Skip to main content
Erschienen in: International Journal of Hematology 4/2009

01.05.2009 | Original Article

Natural history of transfusion-independent non-severe aplastic anemia in children

verfasst von: Nobuhiro Nishio, Hiroshi Yagasaki, Yoshiyuki Takahashi, Hideki Muramatsu, Asahito Hama, Nao Yoshida, Kazuko Kudo, Seiji Kojima

Erschienen in: International Journal of Hematology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Although the known clinical courses of non-severe aplastic anemia (NSAA) in children comprise spontaneous resolution, persistent NSAA, or progression to severe aplastic anemia (SAA), only a few published reports have indicated the outcome of transfusion-independent NSAA. We retrospectively evaluated the incidence and time of progression from transfusion-independent to transfusion-dependent NSAA or SAA. We reviewed the records of 70 children with acquired AA who were referred to our hospital between 1986 and 2006, and among them we found 22 patients who had transfusion-independent NSAA at diagnosis and were treated with supportive care alone until progression to transfusion-dependent AA. 22 patients were followed up for a median of 86 months (range, 11–198 months). The Kaplan-Meier estimates for progression-free survival were 62 ± 12 and 22 ± 13% at 60 and 120 months after diagnosis, respectively. None of the patients treated with supportive care alone improved hematologically. In conclusion, because the incidence of disease progression was high in patients with NSAA, a prospective randomized trial of early intervention with IST or observation alone until disease progression to SAA, followed by IST when the patients become transfusion-dependent is warranted.
Literatur
1.
Zurück zum Zitat Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–14.PubMed Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–14.PubMed
3.
Zurück zum Zitat Gillio AP, Boulad F, Small TN, Kernan NA, Reyes B, Childs BH, et al. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3:18–24.PubMed Gillio AP, Boulad F, Small TN, Kernan NA, Reyes B, Childs BH, et al. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3:18–24.PubMed
4.
Zurück zum Zitat Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–54.PubMed Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–54.PubMed
5.
Zurück zum Zitat Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102–4. doi:10.1182/blood-2005-03-0874.CrossRefPubMed Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102–4. doi:10.​1182/​blood-2005-03-0874.CrossRefPubMed
6.
Zurück zum Zitat Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine: the German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–304.CrossRefPubMed Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine: the German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–304.CrossRefPubMed
7.
Zurück zum Zitat Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058–65.PubMed Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058–65.PubMed
8.
Zurück zum Zitat Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931–4.PubMed Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931–4.PubMed
9.
Zurück zum Zitat Bacigalupo A. Guidelines for the treatment of severe aplastic anemia: Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of bone marrow transplantation (EBMT). Haematologica. 1994;79:438–44.PubMed Bacigalupo A. Guidelines for the treatment of severe aplastic anemia: Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of bone marrow transplantation (EBMT). Haematologica. 1994;79:438–44.PubMed
12.
Zurück zum Zitat Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191–5.PubMed Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191–5.PubMed
13.
Zurück zum Zitat Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102:3584–6. doi:10.1182/blood-2003-04-1032.CrossRefPubMed Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102:3584–6. doi:10.​1182/​blood-2003-04-1032.CrossRefPubMed
15.
Zurück zum Zitat Khatib Z, Wilimas J, Wang W. Outcome of moderate aplastic anemia in children. Am J Pediatr Hematol Oncol. 1994;16:80–5.PubMed Khatib Z, Wilimas J, Wang W. Outcome of moderate aplastic anemia in children. Am J Pediatr Hematol Oncol. 1994;16:80–5.PubMed
16.
17.
Zurück zum Zitat Yagasaki H, Yabe H, Ayukawa H, Noguchi Y, Ijichi O, Kobayashi R, et al. Prospective, randomized, multicenter study comparing antithymocyte globulin (ATG) Alone with ATG Plus Cyclosporine (CsA) for treatment of children with nonsevere aplastic anemia (nSAA). ASH annual meeting abstracts 2005; 106:1043. Yagasaki H, Yabe H, Ayukawa H, Noguchi Y, Ijichi O, Kobayashi R, et al. Prospective, randomized, multicenter study comparing antithymocyte globulin (ATG) Alone with ATG Plus Cyclosporine (CsA) for treatment of children with nonsevere aplastic anemia (nSAA). ASH annual meeting abstracts 2005; 106:1043.
18.
Zurück zum Zitat Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for blood and marrow transplantation (EBMT). Haematologica. 2007;92:11–8. doi:10.3324/haematol.10075.CrossRefPubMed Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for blood and marrow transplantation (EBMT). Haematologica. 2007;92:11–8. doi:10.​3324/​haematol.​10075.CrossRefPubMed
19.
Zurück zum Zitat Kojima S, Inaba J, Yoshimi A, Takahashi Y, Watanabe N, Kudo K, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol. 2001;114:706–11. doi:10.1046/j.1365-2141.2001.02992.x.CrossRefPubMed Kojima S, Inaba J, Yoshimi A, Takahashi Y, Watanabe N, Kudo K, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol. 2001;114:706–11. doi:10.​1046/​j.​1365-2141.​2001.​02992.​x.CrossRefPubMed
Metadaten
Titel
Natural history of transfusion-independent non-severe aplastic anemia in children
verfasst von
Nobuhiro Nishio
Hiroshi Yagasaki
Yoshiyuki Takahashi
Hideki Muramatsu
Asahito Hama
Nao Yoshida
Kazuko Kudo
Seiji Kojima
Publikationsdatum
01.05.2009
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2009
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0302-9

Weitere Artikel der Ausgabe 4/2009

International Journal of Hematology 4/2009 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.